

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 145, PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 23**Complete if Known**

Application Number	10/081,961
Filing Date	February 22, 2002
First Named Inventor	Gorziglia
Art Unit	1653 / 636
Examiner Name	DAVID GUBO
Attorney Docket Number	4-31890A

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
JZ		US- 10/081,969	02-22-2002	Ennist, et al.	
		US- 2001/0006633A1	07-05-2001	Kirn, D.	
		US- 5,672,344	09-30-1997	Kelley, et al.	
		US- 5,677,178	10-14-1997	McCormick, F.	
		US- 5,698,443	12-16-1997	Henderson, et al.	
		US- 5,707,618	01-13-1998	Armentano, et al.	
		US- 5,830,686	11-03-1998	Henderson, D.	
		US- 5,837,511	11-17-1998	Falck-Pedersen, et a	
		US- 5,871,726	02-16-1999	Henderson, et al.	
		US- 5,994,128	11-30-1999	Fallaux, et al.	
		US- 5,998,205	12-07-1999	Hallenbeck, et al.	
		US- 6,057,299	05-02-2000	Henderson, D.	
		US- 6,136,792	10-24-2000	Henderson, D.	
		US- 6,197,293B1	03-06-2001	Henderson, et al.	
		US- 6,254,862B1	07-03-2001	Little, et al.	
		US- 6,271,207B1	08-07-2001	Cristiano, et al.	
		US- 6,297,219B1	10-02-2001	Nabel, et al.	
		US- 6,432,700B1	08-13-2002	Henderson, et al.	
JZ		US- 6,436,394B1	08-20-2002	Henderson, et al.	

RECEIVED

MAY 08 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁴
		Country Code ³ Number ³ Kind Code ³ (if known)				
JZ		WO 92/03563	03-05-1992			
JZ		WO 94/18992	09-01-1994			
JZ		WO 95/19434	07-20-1995			
JZ		WO 96/34969	11-07-1996			
JZ		WO 97/01358	01-16-1997			
JZ		WO 97/04805	02-13-1997			

Examiner
Signature*David Gubo*Date
Considered

12/18/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet 4

of 23

Complete if Known

Application Number	10/081,961
Filing Date	February 22, 2002
First Named Inventor	Gorziglia
Art Unit	1053 / 136
Examiner Name	DAVID GUBO
Attorney Docket Number	4-31890

RECEIVED
MAY

MAY 08 2003

TECH CENTER 8 2003
1600/2900

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)	MM-DD-YYYY		
01		WO 00/03029	01-20-2000		
01		WO 00/15820	03-23-2000		
01		WO 00/22124	04-20-2000		
01		WO 00/29599	05-25-2000		
01		WO 00/31286	06-02-2000		
01		WO 00/39319	06-06-2000		


Examiner Signature	<i>David Gunn</i>	Date Considered	12/18/04
-----------------------	-------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004



PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 8 of 23

Complete if Known

Application Number	10/081,961
Filing Date	February 22, 2002
First Named Inventor	Gorziglia
Art Unit	4653 / 636
Examiner Name	DAVID GUTZ
Attorney Docket Number	4-31890A

RECEIVED

MAY 08 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
je		ADAMS, et al., "Transcriptional Control by E2F," Seminars in Cancer Biology, 6:99-108 (1995)	
		ALEMANY, et al., "Replicative Adenoviruses for Cancer Therapy," Nature Biotechnology, 18:723-727 (July 2000)	
		ANGELICHIO, et al., "Comparison of Several Promoters and Polyadenylation Signals for Use in Heterologous Gene Expression in Cultured Drosophila Cells," Nucleic Acids Research, 19(18):5037-5043 (1991)	
		ARMITAGE, J., "Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," Blood, 92(12):4491-4508 (December 15, 1998)	
		BABISS, et al., "Cellular Promoters Incorporated into the Adenovirus Genome: Effects of Viral Regulatory Elements on Transcription Rates and Cell Specificity of Albumin and Beta-Globin Promoters," Molecular and Cellular Biology, 6(11):3798-3806 (November 1986)	
		BERGSLAND, et al., "Shedding Old Paradigms: Developing Viruses to Treat Cancer," Journal of Clinical Oncology, 20(9):2220-2222 (May 1, 2002)	
		BERT, et al., "Generation of an Improved Luciferase Reporter Gene Plasmid that Employs a Novel Mechanism for High-Copy Replication," Plasmid, 44:173-182 (September 2000)	
		BLACK, et al., "Regulation of E2F: A Family of Transcription Factors Involved in Proliferation Control," Gene, 237:281-302 (1999)	
✓		BRISTOL, et al., "GM-CSF Containing Oncolytic Adenoviruses for the Treatment of Cancer," Abstract No. P2, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002	
je		BRISTOL, et al., "GM-CSF Mediated Stimulation of Innate Anti-tumor Responses," poster presented at the Keystone Symposia, Basic Aspects of Tumor Immunology, February 17-23, 2003	

Examiner Signature	David Gutz	Date Considered	12/18/04
--------------------	------------	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

USPTO Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/081,961
Filing Date	February 22, 2002
First Named Inventor	Gorziglia
Art Unit	1653 / 636
Examiner Name	DAVID GUTZ
Attorney Docket Number	4-31890A

Sheet 9 of 23

RECEIVED
MAY 08 2003
TECH CENTER 1600/2900**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
oe		BRISTOL, et al., "GM-CSF Containing Oncolytic Adenoviruses for the Treatment of Cancer," poster presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002	
		BRISTOL, et al., "In Vivo Anti-Tumor Activity of Oncolytic Adenoviruses that Express GM-CSF in Xenograft Tumor Models," American Society for Gene Therapy, 5th Annual Meeting, June 5-9, 2002; poster presented June 6, 2002	
		BRISTOL, et al., "In Vivo Anti-Tumor Activity of Oncolytic Adenoviruses that Express GM-CSF in Xenograft Tumor Models," Molecular Therapy, 5(5):abstract No. 311 (May 2002)	
		BRUDER, et al., "Nuclear Factor E1-1A Binds to the Adenovirus E1A Core Enhancer Element and to Other Transcriptional Control Regions," Molecular and Cellular Biology, 9(11):5143-5153 (November 1989)	
		BRYAN, et al., "Evidence for an Alternative Mechanism for Maintaining Telomere Length in Human Tumors and Tumor-derived Cell Lines," Nature Medicine, 3(11):1271-1274 (November 1997)	
		CHANG, et al., "Immunogenetic Therapy of Human Melanoma Utilizing Autologous Tumor Cells Transduced to Secrete Granulocyte-Macrophage Colony-Stimulating Factor," Human Gene Therapy, 11:839-850 (April 10, 2000)	
		CHAO, et al., "Assembly of the Cleavage and Polyadenylation Apparatus Requires About 10 Seconds In Vivo and Is Faster for Strong Than for Weak Poly(A) Sites," Molecular and Cellular Biology, 19(8):5588-5600 (August 1999)	
		CHEN, et al., "Antiangiogenic Gene Therapy for Cancer via Systemic Administration of Adenoviral Vectors Expressing Secreted Endostatin," Human Gene Therapy, 11:1983-1996 (September 20, 2000)	
		CHEN, et al., "Cleavage Site Determinants in the Mammalian Polyadenylation Signal," Nucleic Acids Research, 23(14):2614-2620 (1995)	
oe		CHIA, et al., "A Novel Conditionally Oncolytic Adenovirus for the Treatment of Nasopharyngeal Carcinoma (NPC)," Proceedings of the American Association for Cancer Research, 43:1098-1099, abstract No. 5441 (March 2002)	

Examiner
Signature*David Gutz*

Date

Considered

12/18/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004

PTO
MAY 08 2003
OFFICE
PATENT & TRADEMARK

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/081,961
		Filing Date	February 22, 2002
		First Named Inventor	Gorziglia
		Art Unit	1663 / 636
		Examiner Name	DAVID GUZZO
Sheet 10	of 23	Attorney Docket Number	4-31890A

RECEIVED
MAY 08 2003
TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
jc		CHIOCCA, E., "Oncolytic Viruses," Nature, 2:938-950 (December 2002)	
		CHRIST, et al., "Modulation of the Inflammatory Properties and Hepatotoxicity of Recombinant Adenovirus Vectors by the Viral E4 Gene Products," Human Gene Therapy, 11:415-427 (February 10, 2000)	
		COLGAN, et al., "Mechanism and Regulation of mRNA Polyadenylation," Genes and Development, 11:2755-2766 (1997)	
		CURIEL, et al., "Strategies to Improve the Therapeutic Utility of Conditionally Replicative Adenoviruses (CRAds) for Cancer Therapy," Proceedings of the American Association for Cancer Research, 43:662, abstract No. 3287 (March 2002)	
		DEMERS, et al., "Antitumor Efficacy and Replication of an Oncolytic Adenovirus, 01/PEME, in Tumor Tissue Following Intravenous Administration," Proceedings of the American Association for Cancer Research, 43:663, abstract No. 3291 (March 2002)	
		DENOME, et al., "Patterns of Polyadenylation Site Selection in Gene Constructs Containing Multiple Polyadenylation Signals," Molecular and Cellular Biology, 8(11):4829-4839 (November 1988)	
		DeWeese, et al., "A Phase I Trial of CV706, a Replication-Competent, PSA Selective Oncolytic Adenovirus, for the Treatment of Locally Recurrent Prostate Cancer Following Radiation Therapy," Cancer Research, 61:7464-7472 (October 15, 2001)	
		DORONIN, et al., "Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy," Journal of Virology, 75(7):3314-3324 (April 2001)	
		DORONIN, et al., "Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein," Journal of Virology, 74(13):6147-6155 (July 2000)	
jc		DRANOFF, et al., "Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity," Proc. Natl. Acad. Sci. USA, 90:3539-3543 (April 1993)	

Examiner Signature	<i>David Guzzo</i>	Date Considered	12/18/04
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004

O.I.P.F. JCT 08
MAY 08 2003
PATENT & TRADEMARK OFFICE

PTO/SB/089 (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/081,961
Filing Date	February 22, 2002
First Named Inventor	Gorziglia
Art Unit	1653 / 636
Examiner Name	DAVID G. VZD
Attorney Docket Number	4-31890A

RECEIVED
MAY 08 2003

TECH CENTER 1600/2900

Sheet 11 of 23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
jc		DYSON, N., "The Regulation of E2F by pRB-family Proteins," Genes and Development, 12:2245-2262 (August 1998)	
		EMERY, et al., "A Chromatin Insulator Protects Retrovirus Vectors from Chromosomal Position Effects," Proc. Natl. Acad. Sci. USA, 97(16):9150-9155 (August 1, 2000)	
		ENNIST, D., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer," oral presentation at the 4th International Conference, The Adjuvant Therapy of Malignant Melanoma, March 15-16, 2002	
		ENNIST, D., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer," abstract presented at the 4th International Conference, The Adjuvant Therapy of Malignant Melanoma, March 15-16, 2002	
		ENNIST, et al., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer," Proceedings of the American Association for Cancer Research, 43:1098, abstract No. 5437 (March 2002)	
		ENNIST, et al., "Oncolytic Adenoviruses Containing GM-CSF for the Treatment of Cancer," oral presentation at the 93rd Annual Meeting of the American Association for Cancer Research, April 6-10, 2002, San Francisco, California	
		FALLAUX, et al., "New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses," Human Gene Therapy, 9:1909-1917 (September 1, 1998)	
		FANG, et al., "Diminishing Adenovirus Gene Expression and Viral Replication by Promoter Replacement," Journal of Virology, 71(6):4798-4803 (June 1997)	
↓		FRIDOVICH-KEIL, et al., "Improved Expression Vectors for Eukaryotic Promoters-Enhancer Studies," BioTechniques, 11(5):572-579 (1991)	
jc		GANLY, et al., "A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer," Clinical Cancer Research, 6:798-806 (March 2000)	

Examiner Signature	Date Considered
David G. VZD	12/18/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004

PTO
MAY 08 2003
PATENT & TRADEMARK OFFICE

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/081,961
Filing Date February 22, 2002
First Named Inventor Gorziglia
Art Unit 1853 / 636
Examiner Name DAVID GUZO
Attorney Docket Number 4-31890A

RECEIVED
MAY 08 2003
TECH CENTER 1600/2900

Sheet 12 of 23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
RZ		GIL, et al., "Position-Dependent Sequence Elements Downstream of AAUAAA Are Required for Efficient Rabbit α-Globin mRNA 3' End Formation," Cell, 49:399-406 (May 8, 1987)	
		GOPE, et al., "Abundance and State of Phosphorylation of the Retinoblastoma Susceptibility Gene Product in Human Colon Cancer," Molecular and Cellular Biochemistry, 110:123-133 (1992)	
		GU, et al., "Tumor-Specific Transgene Expression from the Human Telomerase Reverse Transcriptase Promoter Enables Targeting of the Therapeutic Effects of the Bax Gene to Cancers," Cancer Research, 60:5359-5364 (October 1, 2000)	
		HABIB, et al., "E1B-Deleted Adenovirus (dl1520) Gene Therapy for Patients with Primary and Secondary Liver Tumors," Human Gene Therapy, 12:219-226 (February 10, 2001)	
		HALLENBECK, et al., "A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma," Human Gene Therapy, 10:1721-1733 (July 1, 1999)	
		HALLENBECK, et al., "Oncolytic Adenoviruses Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the RB-Pathway and Telomerase," American Society of Gene Therapy 5th Annual Meeting, June 5-9, 2002, poster presented on June 5, 2002	
		HALLENBECK, et al., "Oncolytic Adenoviruses Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the RB-Pathway and Telomerase," Molecular Therapy, 5(5):Abstract 165 (May 2002)	
		HALLENBECK, P., "Oncolytic Adenoviruses Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the Rb-Pathway and Telomerase," oral presentation presented at the 3rd International Symposium on Genetic Anticancer Agents, Amsterdam, The Netherlands, March 1-2, 2002	
		HANS, et al., "Functionally Significant Secondary Structure of the Simian Virus 40 Late Polyadenylation Signal," Molecular and Cellular Biology, 20(8):2926-2932 (April 2000)	
HZ		HATFIELD, et al., "Redundant Elements in the Adenovirus Type 5 Inverted Terminal Repeat Promote Bidirectional Transcription In Vitro and Are Important for Virus Growth In Vivo," Virology, 184:265-276 (1991)	

Examiner Signature	<i>David Guzo</i>	Date Considered	12/18/04
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO F JC109
MAY 08 2003

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 13

of 23

Complete if Known	
Application Number	10/081,961
Filing Date	February 22, 2002
First Named Inventor	Gorziglia
Art Unit	1853 / 636
Examiner Name	DAVID G. VZ.
Attorney Docket Number	4-31890A

RECEIVED
MAY 08 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
J		HATFIELD, et al., "The NFIII/OCT-1 Binding Site Stimulates Adenovirus DNA Replication In Vivo and Is Functionally Redundant with Adjacent Sequences," Journal of Virology, 67(7):3931-3939 (July 1993)	
		HAY, C., "Oncolytic Adenovirus Dependent Upon Two Prevalent Alterations in Human Cancer," The 10th Annual Meeting of the European Society of Gene Therapy, Antibes, France, October 13-16, 2002. oral presentation presented on October 16, 2002	
		HEARING, et al., "The Adenovirus Type 5 E1A Transcriptional Control Region Contains a Duplicated Enhancer Element," Cell, 33:695-703 (1983)	
		HEISE, et al., "Efficacy of a Replication-Competent Adenovirus (ONYX-015) Following Intratumoral Injection: Intratumoral Spread and Distribution Effects," Cancer Gene Therapy, 6(6):499-504 (1999)	
		HEISE, et al., "Replication-Selective Adenoviruses as Oncolytic Agents," The Journal of Clinical Investigation, 105(7):847-851 (April 2000)	
		HERMISTON, T., "Gene Delivery From Replication-Selective Viruses: Arming Guided Missiles in the War Against Cancer," The Journal of Clinical Investigation, 105(9):1169-1172 (May 2000)	
		HIYAMA, et al., "Telomerase Activity in Small-Cell and Non-Small-Cell Lung Cancers," Journal of the National Cancer Institute, 87(12):895-902 (June 21, 1995)	
		HORIKAWA, et al., "Cloning and Characterization of the Promoter Region of Human Telomerase Reverse Transcriptase Gene," Cancer Research, 59:826-830 (February 15, 1999)	
		HURFORD, et al., "pRB and p107/p130 are Required for the Regulated Expression of Different Sets of E2F Responsive Genes," Genes & Development, 11:1447-1463 (1997)	
		HWANG, et al., "Polyadenylation of Vesicular Stomatitis Virus mRNA Dictates Efficient Transcription Termination at the Intercistronic Gene Junctions," Journal of Virology, 72(3):1805-1813 (March 1998)	


Examiner Signature	<i>David G. VZ.</i>	Date Considered	12/18/04
--------------------	---------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/081,961
		Filing Date	February 22, 2002
		First Named Inventor	Gorziglia
		Art Unit	1053 / 636
		Examiner Name	DAVID G. V. Z. O
Sheet 14 of 23	Attorney Docket Number	4-31890A	

RECEIVED
MAY 08 2003
TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JL		International Search Report for PCT/US02/05280, February 14, 2003	
		JAFFEE, et al., "Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation," Journal of Clinical Oncology, 19(1):145-156 (January 1, 2001)	
		JAKUBCZAK, et al., "Construction and Characterization of Oncolytic Adenoviruses," Molecular Therapy, 3(5):Abstract 442 (May 2001)	
		JAKUBCZAK, et al., "Construction and Characterization of Oncolytic Adenoviruses," The Fourth Annual Meeting of the American Society of Gene Therapy, May 30-June 3, 2001; poster presented on June 1, 2001	
		JAKUBCZAK, et al., "Evaluation of In Vivo Selectivity of Oncolytic Adenoviruses Following Intravenous Administration in SCID Mice Using Toxicological and Molecular Parameters," American Society of Gene Therapy, 5th Annual Meeting, June 5-9, 2002; poster presented June 7, 2002	
		JAKUBCZAK, et al., "Evaluation of In Vivo Selectivity of Oncolytic Adenoviruses Following Intravenous Administration in SCID Mice Using Toxicological and Molecular Parameters," Molecular Therapy, 5(5):abstract No. 851 (March 2002)	
		JAKUBCZAK, J., "An Oncolytic Adenovirus Dependent Upon Two Prevalent Alterations in Human Cancer; Disregulation of the Rb-Pathway and Telomerase," oral presentation presented at the US-Japan Cooperative Cancer Research Program, Telomeres and Telomerase in Cancer Research, Maui, HI, August 3-5, 2002	
		JOHNSON, et al., "Autoregulatory Control of E2F1 Expression in Response to Positive and Negative Regulators of Cell Cycle Progression," Genes and Development, 8:1514-1525 (1994)	
		JOHNSON, et al., "Cytosine Deaminase-armed Selectively Replicating Adenovirus for the Treatment of Cancer," Proceedings of the American Association for Cancer Research, 43:656, abstract No. 3257 (March 2002)	
JL		JOHNSON, et al., "Selectively Replicating Adenoviruses Targeting Deregulated E2F Activity are Potent, Systemic Antitumor Agents," Cancer Cell, 1:325-337 (May 2002)	


Examiner Signature	<i>David G. V. Z. O</i>	Date Considered	12/18/04
--------------------	-------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 15

of

23

Complete if Known

Application Number	10/081,961
Filing Date	February 22, 2002
First Named Inventor	Gorziglia
Art Unit	1653 / 636
Examiner Name	DAVID GURZIO
Attorney Docket Number	4-31890A

RECEIVED
MAY 08 2003
TECH CENTER 1600/2900**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
g		KAELIN, et al., "Expression Cloning of a cDNA Encoding a Retinoblastoma-Binding Protein with E2F-like Properties," Cell, 70:351-364 (July 24, 1992)	
		KESSLER, et al., "Requirement of A-A-U-A-A and Adjacent Downstream Sequences for SV40 Early Polyadenylation," Nucleic Acids Research, 14(12):4939-4953 (1986)	
		KILIAN, et al., "Isolation of a Candidate Human Telomerase Catalytic Subunit Gene, Which Reveals Complex Splicing Patterns in Different Cell Types," Human Molecular Genetics, 6(12):2011-2019 (1997)	
		KIM, et al., "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer," Science, 266:2011-2015 (December 23, 1994)	
		KIRN, D., "Clinical Research Results with dl1520 (Onyx-015), a Replication-selective Adenovirus for the Treatment of Cancer: What Have We Learned?" Gene Therapy, 8:89-98 (January 2001)	
		KIRN, D., "Replication-selective Microbiological Agents: Fighting Cancer With Targeted Germ Warfare," The Journal of Clinical Investigation, 105(7):837-839 (April 2000)	
		KIRN, D., "Replication-selective Oncolytic Adenoviruses: Virotherapy Aimed at Genetic Targets in Cancer," Oncogene, 19:6660-6669 (December 27, 2000)	
		KIRN, D., "Virotherapy for Cancer: Current Status, Hurdles, and Future Directions," Cancer Gene Therapy, 9:959-960 (December 2002)	
		KIRN, et al., "ONYX-015: Clinical Data are Encouraging," Nature Medicine, 4(12):1341-1342 (December 1998)	
✓		KIRSCHWEGER, G., "Genetic Therapies, Inc.: Tight-Lipped for Now," Molecular Therapy, 7(3):293 (March 2003)	

Examiner
Signature*David Gurzio*

Date

Considered


12/18/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 16

of

23

Complete if Known

Application Number 10/081,961

Filing Date February 22, 2002

First Named Inventor Gorziglia

Art Unit 1653

Examiner Name

Attorney Docket Number 4-31890A

RECEIVED

MAY 08 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JK		KIYONO, et al., "Both Rb/p16INK4a Inactivation and Telomerase Activity are Required to Immortalize Human Epithelial Cells," Nature, 396:84-88 (November 5, 1998)	
		KOVESDI, et al., "Identification of a Cellular Transcription Factor Involved in E1A Trans-Activation," Cell, 45:219-228 (April 25, 1986)	
		KURIHARA, et al., "Selectivity of a Replication-Competent Adenovirus for Human Breast Carcinoma Cells Expressing the MUC1 Antigen," The Journal of Clinical Investigation, 106(6):763-771 (September 2000)	
		KWONG, et al., "Combination Therapy with Suicide and Cytokine Genes for Hepatic Metastases of Lung Cancer," Chest, 112(5):1332-1337 (November 1997)	
		LA THANGUE, N., "DRTF 1/E2F: An Expanding Family of Heterodimeric Transcription Factors Implicated in Cell-Cycle Control," Trends in Biochemical Science, 19:108-114 (March 1994)	
		LI, et al., "A Hepatocellular Carcinoma-specific Adenovirus Variant, CV890, Eliminates Distant Human Liver Tumors in Combination with Doxorubicin," Cancer Research, 61:6428-6436 (September 1, 2001)	
		LI, et al., "Replication Competent Oncolytic Adenovirus for Colon Cancer Therapy," Proceedings of the American Association for Cancer Research, 43:858, abstract No. 4251 (March 2002)	
		LIMBACH, et al., "Development of Adenovirus Serotype 35 as a Gene Transfer Vector," poster presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002	
		LIU, et al., "Optimised Oncolytic Herpes Simplex Virus for Cancer Treatment," Abstract No. Or33, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002	
JK		LIU, et al., "Optimized Oncolytic Herpes Simplex Virus for Cancer Treatment," poster presented at the 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002	

Examiner
Signature

Date

Considered


12/18/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.



PTO/SB/088 (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Institute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 17

of

23

Complete if Known	
Application Number	10/081,961
Filing Date	February 22, 2002
First Named Inventor	Gorziglia
Art Unit	1853 / 636
Examiner Name	DAVID GUZZO
Attorney Docket Number	4-31890A

RECEIVED

MAY 08 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
jl		LORENCE, et al., "Systemic Therapy of Human Tumor Xenografts Using PV701, an Oncolytic Strain of Newcastle Disease Virus, in Combination with a Cytotoxic Drug Demonstrates at Least Additive Antitumor Responses," Proceedings of the American Association for Cancer Research, 43:1096, abstract No. 5428 (March 2002)	
		LYONS, R., "Multiple Approaches to Treating Systemic Disease with Oncolytic Adenoviruses," ASM Gene Therapy Conference, February 28, 2003, Banff, Alberta CA; oral presentation presented February 28, 2003	
		MABJEESH, et al., "Gene Therapy of Prostate Cancer: Current and Future Directions," Endocrine-Related Cancer, 9:115-139 (June 2002)	
		McDEVITT, et al., "Sequences Capable of Restoring poly(A) Site Function Define Two Distinct Downstream Elements," The EMBO Journal, 5(11):2907-2913 (1986)	
		MEDINA, et al., "Adenovirus-Mediated Cytotoxicity of Chronic Lymphocytic Leukemia Cells," Blood, 94(10):3499-3508 (November 15, 1999)	
		MORRIS, et al., "Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk," Molecular Therapy, 1(1):56-62 (January 2000)	
		NEMUNAITIS, et al., "Selective Replication and Oncolysis in p53 Mutant Tumors with ONYX-015, an E1B-55kD Gene-Deleted Adenovirus, in Patients with Advanced Head and Neck Cancer: A Phase II Trial," Cancer Research, 60:6359-6366 (November 15, 2000)	
		NEUMAN, et al., "Structure and Partial Genomic Sequence of the Human E2F1 Gene," Gene, 173:163-169 (1996)	
		NEUMAN, et al., "Transcription of the E2F-1 Gene is Rendered Cell Cycle Dependent by E2F DNA-Binding Sites Within its Promoter," Molecular and Cellular Biology, 14(10):6607-6615 (October 1994)	
jl		OH, et al., "In Vivo and In Vitro Analyses of Myc for Differential Promoter Activities of the Human Telomerase (hTERT) Gene in Normal and Tumor Cells," Biochemical and Biophysical Research Communications, 263:361-365 (1999)	

Examiner Signature	<i>David Guzzo</i>	Date Considered	12/13/04
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004



PTO/SB/088 (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 18

of

23

Complete if Known

Application Number	10/081,961
Filing Date	February 22, 2002
First Named Inventor	Gorziglia
Art Unit	1853 / 636
Examiner Name	DAVID GUZO
Attorney Docket Number	4-31890A

RECEIVED
MAY 08 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2		PAIELLI, et al., "Evaluation of the Biodistribution, Persistence, Toxicity, and Potential of Germ-Line Transmission of a Replication-Competent Human Adenovirus Following Intraprostatic Administration in the Mouse," Molecular Therapy, 1(3):263-274 (March 2000)	
		PARDOLL, D., "Paracrine Cytokine Adjuvants in Cancer Immunotherapy," Annu. Rev. Immunol., 13:399-415 (1995)	
		PARR, et al., "Tumor-selective Transgene Expression In Vivo Mediated by an E2F-responsive Adenoviral Vector," Nature Medicine, 3(10):1145-1149 (October 1997)	
		PECORA, et al., "Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers," Journal of Clinical Oncology, 20(9):2251-2266 (May 1, 2002)	
		PETER, et al., "A Novel Attenuated Replication-Competent Adenovirus for Melanoma Therapy," Abstract No. P78, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002	
		POOLE, et al., "Activity, Function, and Gene Regulation of the Catalytic Subunit of Telomerase (hTERT)," Gene, 269:1-12 (May 2001)	
		POROSNICU, et al., "Increased Efficiency of the Selectively Oncolytic Vesicular Stomatitis Virus by Genetic Manipulation with Expression of Suicide Genes," Proceedings of the American Association for Cancer Research, 43:1096-1097, abstract No. 5431 (March 2002),	
		POWELL, et al., "A Conditionally Replicative Adenovirus Driven by the Human Telomerase Promoter Provides Broad-Spectrum Anti-Tumor Activity," Molecular Therapy, 5(5):abstract No. 51 (May 2002)	
		PRELL, et al., "Tumor Necrosis Factor (-armed Defective p53-pathway Selective Replicating Adenovirus for Cancer Treatment," Proceedings of the American Association for Cancer Research, 43:1110, abstract No. 5500 (March 2002)	
02		RAMACHANDRA, et al., "Re-engineering Adenovirus Regulatory Pathways to Enhance Oncolytic Specificity and Efficacy," Nature Biotechnology, 19:1035-1041 (November 2001)	

Examiner Signature	<i>David Guzo</i>	Date Considered	12/18/04
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004



PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/081,961
		Filing Date	February 22, 2002
		First Named Inventor	Gorziglia
		Art Unit	1663-1636
		Examiner Name	DAVID GUZO
Sheet 19 of 23	Attorney Docket Number	4-31890A	

RECEIVED

MAY 08 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓		RASCHKE, et al., "A Replication Competent Dual-ad Vector for Treatment of Prostate Cancer," Abstract No. Or41, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002	
		RASSA, et al., "Molecular Basis for Naturally Occurring Elevated Readthrough Transcription Across the M-F Junction of the Paramyxovirus SV5," Virology, 247:274-286 (1998)	
		REDDY, et al., "Development of Adenovirus Serotype 35 as a Gene Transfer Vector," American Society of Gene Therapy 5th Annual Meeting, June 5-9, 2002, poster presented June 6, 2002	
		REDDY, et al., "Development of Adenovirus Serotype 35 as a Gene Transfer Vector," American Society of Gene Therapy 5th Annual Meeting, June 5-9, 2002, Molecular Therapy, 5(5):S67-S68, abstract No. 200	
		RESZKA, et al., "New Targeting System for High-efficient Delivery of Anti-neoplastic Drugs or Genes into the Angiogenetic Areas of Liver Tumors," Proceedings of the American Association for Cancer Research, 43:663, abstract No. 3289 (March 2002)	
		RIES, et al., "ONYX-015: Mechanisms of Action and Clinical Potential of a Replication-Selective Adenovirus," British Journal of Cancer, 86:5-11 (January 7, 2002)	
		RODRIGUEZ, et al., "Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells," Cancer Research, 57:2559-2563 (July 1, 1997)	
		RUSSELL, W., "Update on Adenovirus and Its Vectors," Journal of General Virology, 81:2573-2604 (November 2000)	
✓		RYAN, et al., "An Oncolytic Adenovirus Dependent on Two Prevalent Alterations in Human Cancer: Efficacy, Tolerability, and Tumor-Selectivity Following Systemic Administration," Eleventh International Conference on Gene Therapy of Cancer, San Diego, CA, December 12-14, 2002, 10(Suppl. 1):abstract No. 036	
✓		RYAN, et al., "Anti-Tumor Efficacy and Predclinical Proof-of-Concept Following Systemic Administration of an Oncolytic Adenovirus Dependent Upon Two Prevalent Alterations in Human Cancer," Abstract No. Or34, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002	

Examiner Signature	<i>David Guzo</i>	Date Considered	12/18/04
--------------------	-------------------	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004



PTO/SB/088 (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 20

of

23

Complete if Known

Application Number 10/081,961
Filing Date February 22, 2002
First Named Inventor Gorziglia
Art Unit 4653 / 636
Examiner Name DAVID GUZ
Attorney Docket Number 4-31890A

RECEIVED

MAY 08 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
gc		SANCHEZ-PRieto, et al., "Lack of Correlation Between p53 Protein Level and Sensitivity to DNA-damaging Agents in Keratinocytes Carrying Adenovirus E1a Mutants," Oncogene, 11:675-682 (1995)	
		SAUTHOFF, et al., "Deletion of the Adenoviral E1b-19kD Gene Enhances Tumor Cell Killing of a Replicating Adenoviral Vector," Human Gene Therapy, 11:379-388 (February 10, 2000)	
		SAUTHOFF, et al., "p53 Expression Late in the Life Cycle of a Replication-competent Adenovirus Improves Tumor Cell Killing and Deletion of the Death Protein Improves Specificity," Proceedings of the American Association for Cancer Research, 43:1098, abstract No. 5439 (March 2002)	
		SCHWARZ, et al., "Interactions of the p107 and Rb Proteins with E2F During the Cell Proliferation Response," The EMBO Journal, 12(3):1013-1020 (1993)	
		SELLERS, et al., "A Potent Transrepression Domain in the Retinoblastoma Protein Induces a Cell Cycle Arrest When Bound to E2F Sites," Proc. Natl. Acad. Sci. USA, 92:11544-11548 (December 1995)	
		SHAY, et al., "A Survey of Telomerase Activity in Human Cancer," European Journal of Cancer, 33(5):787-791 (1997)	
		SHAY, et al., "Telomerase and Cancer," Human Molecular Genetics, 10(7):677-685 (April 2001)	
		SHI, et al., "Modulation of the Specificity and Activity of a Cellular Promoter in an Adenoviral Vector," Human Gene Therapy, 8:403-410 (March 1, 1997)	
		STEINWAEDER, et al., "Insulation from Viral Transcriptional Regulatory Elements Improves Inducible Transgene Expression from Adenovirus Vectors In Vitro and In Vivo," Gene Therapy, 7(7):556-567 (April 2000)	
gc		STEWART, D., "Oncolytic Adenovirus Dependent on Two Prevalent Alterations in Human Cancer," oral presentation presented at the Eleventh International Conference on Gene Therapy of Cancer, San Diego, CA, December 12-14, 2002	

Examiner Signature

David Guz

Date

Considered

12/18/04


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004



PTO/SB/088 (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 21

of 23

Complete if Known

Application Number	10/081,961
Filing Date	February 22, 2002
First Named Inventor	Gorziglia
Art Unit	1855 / 636
Examiner Name	DAVID G. VERO
Attorney Docket Number	4-31890A

RECEIVED
MAY 08 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JL		STEWART, et al., "OAV001, an Oncolytic Adenovirus Dependent on Rb-Pathway Alterations in Human Cancer," American Society for Gene Therapy, 5th Annual Meeting, June 5-9, 2002; oral presentation presented June 7, 2002	
		STEWART, et al., "OAV001, an Oncolytic Adenovirus Dependent on Rb-Pathway Alterations in Human Cancer," Molecular Therapy, 5(5):abstract No. 53 (May 2002)	
		STEWART, et al., "Telomerase and Human Tumorigenesis," Seminars in Cancer Biology, 10:399-406 (December 2000)	
		STRAUSS, et al., "Unrestricted Cell Cycling and Cancer," Nature Medicine, 1(12):1245-1246 (December 1995)	
		TAKAHASHI, et al., "Analysis of Promoter Binding by the E2F and pRB Families In Vivo: Distinct E2F Proteins Mediate Activation and Repression," Genes & Development, 14:804-816 (April 1, 2000)	
		TAKAKURA, et al., "Cloning of Human Telomerase Catalytic Subunit (hTERT) Gene Promoter and Identification of Proximal Core Promoter Sequences Essential for Transcriptional Activation in Immortalized and Cancer Cells," Cancer Research, 59:551-557 (February 1, 1999)	
		TERHUNE, et al., "Regulation of Human Papillomavirus Type 31 Polyadenylation During the Differentiation-Dependent Life Cycle," Journal of Virology, 73(9):7185-7192 (September 1999)	
		TEVOSIAN, et al., "Expression of the E2F-1/DP-1 Transcription Factor in Murine Development," Cell Growth and Differentiation, 7:43-52 (January 1996)	
		TOLLEFSON, et al., "The Adenovirus Death Protein (E3-11.6K) Is Required at Very Late Stages of Infection for Efficient Cell Lysis and Release of Adenovirus from Infected Cells," Journal of Virology, 70(4):2296-2306 (April 1996)	
DL		TSUKUDA, et al., "An E2F-responsive Replication-selective Adenovirus Targeted to the Defective Cell Cycle in Cancer Cells: Potent Antitumoral Efficacy but No Toxicity to Normal Cells," Cancer Research, 62:3438-3447 (June 15, 2002)	


Examiner Signature	Date Considered
<i>David G. Vero</i>	12/18/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/081,961
Filing Date	February 22, 2002
First Named Inventor	Gorziglia
Art Unit	TECH 1636
Examiner Name	DAVID G. UZO
Attorney Docket Number	4-31890A

RECEIVED

MAY 08 2003

TECH CENTER 1600/2900

Sheet 22 of 23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓		VASSAUX, et al., "Insulation of a Conditionally Expressed Transgene in an Adenoviral Vector," Gene Therapy, 6:1192-1197 (1999)	
		VILE, et al., "The Oncolytic Virotherapy Treatment Platform for Cancer: Unique Biological and Biosafety Points to Consider," Cancer Gene Therapy, 9:1062-1067 (December 2002)	
		WAEHLER, et al., "Experimental Gene Therapy of Hepatocellular Carcinoma: Expression of IL-12, 4-1BBL and IL-2 From a Single Adenoviral Vector," Abstract No. P33, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002	
		WAHLE, et al., "The Mechanism of 3' Cleavage and Polyadenylation of Eukaryotic Pre-mRNA," Progress in Nucleic Acid Research and Molecular Biology, 57:41-71 (1997)	
		WEINBERG, R., "The Retinoblastoma Protein and Cell Cycle Control," Cell, 81:323-330 (May 5, 1995)	
		WEN, et al., "Effect of Viral Replication on Pharmacokinetics of 01/PEME, a Recombinant Oncolytic Adenovirus, in a Human Lung Cancer Xenograft Model," Proceedings of the American Association for Cancer Research, 43:1098, abstract No. 5440 (March 2002)	
		WOLD, et al., "Adenovirus Proteins that Subvert Host Defenses," Trends in Microbiology, 2(11):437-443 (November 1994)	
		WOLD, et al., "Immune Responses to Adenoviruses: Viral Evasion Mechanisms and Their Implications for the Clinic," Current Opinion in Immunology, 11:380-386 (1999)	
		YU, et al., "Identification of the Transcriptional Regulatory Sequences of Human Kallikrein 2 and Their Use in the Construction of Calydon Virus 764, an Attenuated Replication Competent Adenovirus for Prostate Cancer Therapy," Cancer Research, 59:1498-1504 (April 1, 1999)	
✓		YU, et al., "The Addition of Adenovirus Type 5 Region E3 Enables Calydon Virus 787 to Eliminate Distant Prostate Tumor Xenografts," Cancer Research, 59:4200-4203 (September 1, 1999)	


Examiner Signature	Date Considered
<i>David G. Uzo</i>	12/18/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Copied from 10206747 on 07-04-2004



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
(Use as many sheets as necessary)		Application Number	10/081,961
		Filing Date	February 22, 2002
		First Named Inventor	Gorziglia
		Art Unit	1636
		Examiner Name	DAVID G. V. Z.
Sheet 23 of 23	Attorney Docket Number	4-31890A	

RECEIVED MAY 08 2003 TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RL		ZHOU, et al., "E1A Sensitizes HER2/neu-overexpressing Ewing's Sarcoma Cells to Topoisomerase II-targeting Anticancer Drugs," Cancer Research, 61:3394-3398 (April 15, 2001)	
RL		ZHU, et al., "In Vivo Spread of Oncolytic Adenoviruses in Xenograft Tumor Models," Molecular Therapy, 5(5):abstract No. 317 (May 2002)	
A		ZSENGELLER, et al., "Adenovirus-Mediated Granulocyte-Macrophage Colony-Stimulating Factor Improves Lung Pathology of Pulmonary Alveolar Proteinosis in Granulocyte-Macrophage Colony-Stimulating Factor-Deficient Mice," Human Gene Therapy, 9:2101-2109 (September 20, 1998)	
JA		ZWICKER, et al., "Cell Cycle-regulated Transcription in Mammalian Cells," Progress in Cell Cycle Research, 1:91-99 (1995)	
RL		DONG, et al., "Angiostatin-Mediated Suppression of Cancer Metastases by Primary Neoplasms Engineered to Produce Granulocyte/Macrophage Colony-Stimulating Factor," J. Exp. Med., 188(4):755-763 (August 17, 1998)	

Examiner Signature	<i>David G. V. Z.</i>	Date Considered	12/18/04
--------------------	-----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.